

Comparison of Contrast Enhanced UltraSound to Magnetic Resonance Imaging for the detection of synovitis in patients with haemophilic arthropathy. A pilot study

ACTRN12614000662662

Status	RECRUITING
Sponsor	Dr Anne Powell
Enrollment	40 participants

Plain Language Summary

People with haemophilia — a bleeding disorder — can develop joint damage called haemophilic arthropathy, where joint bleeding causes chronic swelling and inflammation in the joint lining (synovitis). This pilot study is testing whether contrast-enhanced ultrasound (CEUS) — an ultrasound technique using a contrast agent injected into the bloodstream — is as good as MRI (the current standard test) for detecting synovitis. If so, CEUS could offer a faster, less claustrophobic alternative to MRI.

You may be eligible if:

- You are between 18 and 70 years old
- You have been diagnosed with haemophilic arthropathy
- Physical examination alone cannot clearly confirm whether you have synovitis (joint inflammation)

You may NOT be eligible if:

- You are pregnant or breastfeeding
- You have a right-to-left cardiovascular shunt or pulmonary hypertension
- You have kidney impairment
- You have unstable heart disease
- You have a known allergy to ultrasound contrast agents

Talk to your doctor about whether this trial might be right for you.

Key Eligibility Criteria

Inclusion (1)

- Adult patients with haemophilic arthropathy

Exclusion (1)

- Pregnancy or breast feeding, right to left cardiovascular shunts, pulmonary hypertension, renal impairment, unstable cardiac disease, hypersensitivity to contrast agents

Locations (1 total)

VIC, Australia

<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12614000662662>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at anzctr.org.au. Generated by ClinicalTrialsFinder.org.